Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of a Pharmacodynamic Biomarker of Opioid Antagonism in Adolescents With Eating Disorders

NCT05509257 is registered in ClinicalTrials.gov with Children's Mercy Hospital Kansas City as lead sponsor.

NCT NCT05509257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05509257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of a Pharmacodynamic Biomarker of Opioid Antagonism in Adolescents With Eating Disorders
Lead sponsor
Children's Mercy Hospital Kansas City
Phase
Phase 1
Overall status
Recruiting
Start date
September 17, 2022
Completion date
June 30, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anorexia nervosa, atypical, binge eating, bulimia nervosa, eating disorders, purging (eating disorders)